May 27, 2008Circulation
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
Why the study?
Does ambrisentan improve 6-minute walk distance in patients with pulmonary arterial hypertension?
Population
394 patients with pulmonary arterial hypertension (202 in ARIES-1 and 192 in ARIES-2)
Comparison
Ambrisentan orally once daily for 12 weeks vs Placebo
Design
RCT, randomized, double-blind
Follow-up
12 weeks (with a 48-week extension study)
Authors
Discussion
Loading...
Member takes
Implication
Supports ambrisentan initiation to improve functional capacity in PAH; confirms selective ETA antagonism benefit in RCTs.
Structured PICO
Does ambrisentan improve 6-minute walk distance in patients with pulmonary arterial hypertension?
P
Population
394 patients with pulmonary arterial hypertension (202 in ARIES-1 and 192 in ARIES-2)
I
Intervention
Ambrisentan orally once daily (5 or 10 mg in ARIES-1; 2.5 or 5 mg in ARIES-2) for 12 weeks
C
Comparator
Placebo
O
Outcome
Change in 6-minute walk distance from baseline to week 12surrogate
Ambrisentan significantly improves exercise capacity and is well tolerated with a low risk of aminotransferase abnormalities in patients with pulmonary arterial hypertension.
Cite This Study
Galiè et al. (2008) studied this question.